AnHeart Therapeutics
Xin (Shaun) Yang has work experience in the field of data management. Xin (Shaun) is currently working as a Senior DM Manager at AnHeart Therapeutics since July 2021. Prior to this, they worked at Parexel as a DML II from September 2018 to June 2021. Before that, they were employed at Rundo as a Data Manager / DM Supervisor from June 2012 to September 2018, and at rundo-cronova as a Data Manager from June 2010 to June 2012.
From 2007 to 2010, Xin (Shaun) Yang pursued a Master's degree in Microbial and Biochemical Pharmacy at "Jobs for young freshers".
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.